Genomic Health Announces Third Quarter 2009 Financial Results and Busines...(Condensed Consolidated Statements of Ope...),Health

Date:11/4/2009

Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2009 2008 2009 2008 ---------- ---------- ---------- ---------- Revenues: Product revenues $38,910 $28,070 $107,529 $ 77,752 Contract revenues 607 51 2,436 1,592 ---------- ---------- ---------- ---------- Total revenues 39,517 28,121 109,965 79,344 Operating expenses: Cost of product revenues 8,301 7,140 24,019 19,875 Research and development 9,120 6,939 27,007 20,667 Selling and marketing 15,313 10,837 45,719 35,030 General and administrative 7,316 6,505 22,318 18,635 ---------- ---------- ---------- ---------- Total operating expenses 40,050 31,421 119,063 94,207 ---------- ---------- ---------- ---------- Loss from operations (533) (3,300) (9,098) (14,863) Interest and other income, net 116 369 591 1,438 Interest and other expense, net (22) (91) (109) (330) ---------- ---------- ---------- ---------- Loss before income taxes (439) (3,022) (8,616) (13,755) Provision for income taxes (63) - (454) - ---------- ---------- ---------- ---------- Net
'/>"/>

SOURCE Genomic Health, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference